Symbols / CERO
CERO Chart
About
CERo Therapeutics Holdings, Inc., an immunotherapy company, focuses on advancing the development of engineered T cell therapeutics for the treatment of cancer. Its lead development candidate is CER-1236, an autologous T cell therapy candidate for the treatment of hematologic malignancies and solid tumors. The company was incorporated in 2021 and is based in South San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 886.31K |
| Enterprise Value | 8.57M | Income | -49.19M | Sales | — |
| Book/sh | -8.85 | Cash/sh | 0.09 | Dividend Yield | — |
| Payout | 0.00% | Employees | 8 | IPO | — |
| P/E | — | Forward P/E | -0.02 | PEG | — |
| P/S | — | P/B | -0.00 | P/C | — |
| EV/EBITDA | -0.50 | EV/Sales | — | Quick Ratio | 0.23 |
| Current Ratio | 0.30 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -2.80 | EPS next Y | -2.50 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-19 16:00 | ROA | -210.22% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 21.10M |
| Shs Float | 21.07M | Short Float | 10.50% | Short Ratio | 0.83 |
| Short Interest | — | 52W High | 35.00 | 52W Low | 0.04 |
| Beta | 0.30 | Avg Volume | 466.64K | Volume | 96.93K |
| Target Price | — | Recom | None | Prev Close | $0.04 |
| Price | $0.04 | Change | 2.44% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.04
Latest analyst target
3. DCF / Fair value
$-6.70
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.04
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-18 | down | D. Boral Capital | Buy → Hold | — |
| 2025-10-30 | main | D. Boral Capital | Buy → Buy | $30 |
| 2025-10-22 | main | D. Boral Capital | Buy → Buy | $30 |
| 2025-10-13 | main | D. Boral Capital | Buy → Buy | $30 |
| 2025-09-23 | main | D. Boral Capital | Buy → Buy | $30 |
| 2025-09-09 | main | D. Boral Capital | Buy → Buy | $30 |
| 2025-09-05 | main | D. Boral Capital | Buy → Buy | $30 |
| 2025-08-04 | main | D. Boral Capital | Buy → Buy | $30 |
| 2025-06-24 | main | D. Boral Capital | Buy → Buy | $30 |
| 2025-06-23 | up | D. Boral Capital | Hold → Buy | $30 |
| 2025-05-30 | down | D. Boral Capital | Buy → Hold | — |
| 2025-05-19 | init | Maxim Group | — → Buy | $3 |
| 2025-04-25 | main | D. Boral Capital | Buy → Buy | $11 |
| 2025-04-23 | main | D. Boral Capital | Buy → Buy | $11 |
| 2025-04-22 | init | D. Boral Capital | — → Buy | $11 |
- Ex-SCYNEXIS CFO who raised $300M joins CERo cancer board - Stock Titan ue, 17 Feb 2026 13
- CERo Therapeutics Holdings (CERO) Price Target Increased by 33.33% to 30.60 - Nasdaq Mon, 17 Nov 2025 08
- Cero Therapeutics shareholders approve equity plan amendment and reverse stock split - Investing.com Fri, 19 Dec 2025 08
- CERo Therapeutics Securities Delisted Following Nasdaq Appeal Denial - TipRanks ue, 03 Feb 2026 08
- CERo Therapeutics Completes First Tranche of $7 Million Financing to Support Clinical Development and Nasdaq Compliance - Quiver Quantitative ue, 21 Oct 2025 07
- CERo Therapeutics Sits On A High-Risk, High-Reward Biotech Bet - Finimize Sat, 23 Aug 2025 15
- CERo Therapeutics Announces Listing on OTC Markets - Yahoo Finance Mon, 03 Nov 2025 08
- CERo Therapeutics (NASDAQ: CERO) denied over $2.5M equity rule; suspended Oct. 31 - Stock Titan Wed, 29 Oct 2025 07
- CERo Therapeutics Holdings, Inc. Issues Additional Series D Preferred Stock Shares to Institutional Investors for Up to $8 Million - Nasdaq Fri, 06 Jun 2025 07
- Cero Therapeutics announces 1-for-20 reverse stock split - Yahoo Finance hu, 12 Jun 2025 07
- Why Is CERo Therapeutics Stock Down 80% Today? - TipRanks hu, 30 Oct 2025 07
- Early-stage cell therapy trial tests higher-dose treatment for AML - Stock Titan Wed, 17 Dec 2025 08
- New Analyst Forecast: $CERO Given 'Hold' Rating | CERO Stock News - Quiver Quantitative Mon, 03 Nov 2025 08
- CERo Therapeutics Announces Convertible Note Financing and New Director - TipRanks Fri, 13 Feb 2026 08
- Leukemia trial patient goes 61 days without platelet transfusion - Stock Titan Wed, 07 Jan 2026 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 294460 | 29.0 | — | Conversion of Exercise of derivative security at price 0.00 per share. | ATWOOD BRIAN G | Director | — | 2025-03-31 00:00:00 | I |
| 1 | 5957250 | 400456.0 | — | Sale at price 0.06 - 0.08 per share. | YK BIOVENTURES OPPORTUNITIES GP I, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | — | 2024-12-13 00:00:00 | I |
| 2 | 3658364 | 383370.0 | — | Sale at price 0.09 - 0.12 per share. | YK BIOVENTURES OPPORTUNITIES GP I, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | — | 2024-12-10 00:00:00 | I |
| 3 | 3250000 | 325000.0 | — | Sale at price 0.10 per share. | YK BIOVENTURES OPPORTUNITIES GP I, L.L.C. | Beneficial Owner of more than 10% of a Class of Security | — | 2024-10-10 00:00:00 | I |
| 4 | 532486 | 55538.0 | — | Sale at price 0.10 per share. | SLOAN STUART M | Beneficial Owner of more than 10% of a Class of Security | — | 2024-09-25 00:00:00 | I |
| 5 | 965997 | nan | — | — | LAPORTE KATHLEEN D | Director | — | 2024-09-25 00:00:00 | I |
| 6 | 19358578 | nan | — | — | ATWOOD BRIAN G | Director | — | 2024-09-25 00:00:00 | I |
| 7 | 5312983 | nan | — | — | EHRLICH CHRISTOPHER B | Chief Executive Officer | — | 2024-09-25 00:00:00 | D |
Financials
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -6.87M | -10.90M | -10.88M |
| TotalUnusualItems | 309.31K | ||
| TotalUnusualItemsExcludingGoodwill | 309.31K | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -7.29M | -11.83M | -10.63M |
| ReconciledDepreciation | 1.12M | 1.07M | 735.47K |
| EBITDA | -6.56M | -10.90M | -10.88M |
| EBIT | -7.68M | -11.97M | -11.62M |
| NetInterestIncome | 138.34K | 142.12K | 986.71K |
| InterestIncome | 138.34K | 142.12K | 986.71K |
| NormalizedIncome | -7.60M | -11.83M | -10.63M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -7.29M | -11.83M | -10.63M |
| TotalExpenses | 7.68M | 11.97M | 11.62M |
| TotalOperatingIncomeAsReported | -7.68M | -11.97M | -11.62M |
| DilutedAverageShares | 5.96K | 4.53K | 4.53K |
| BasicAverageShares | 5.96K | 4.53K | 4.53K |
| DilutedEPS | -1.42K | -2.61K | -2.35K |
| BasicEPS | -1.42K | -2.61K | -2.35K |
| DilutedNIAvailtoComStockholders | -7.29M | -11.83M | -10.63M |
| NetIncomeCommonStockholders | -7.29M | -11.83M | -10.63M |
| OtherunderPreferredStockDividend | 0.00 | ||
| NetIncome | -7.29M | -11.83M | -10.63M |
| NetIncomeIncludingNoncontrollingInterests | -7.29M | -11.83M | -10.63M |
| NetIncomeContinuousOperations | -7.29M | -11.83M | -10.63M |
| PretaxIncome | -7.29M | -11.83M | -10.63M |
| OtherIncomeExpense | 247.13K | ||
| OtherNonOperatingIncomeExpenses | -62.18K | ||
| SpecialIncomeCharges | 8.14K | ||
| OtherSpecialCharges | -8.14K | ||
| GainOnSaleOfSecurity | 301.17K | ||
| NetNonOperatingInterestIncomeExpense | 138.34K | 142.12K | 986.71K |
| InterestIncomeNonOperating | 138.34K | 142.12K | 986.71K |
| OperatingIncome | -7.68M | -11.97M | -11.62M |
| OperatingExpense | 7.68M | 11.97M | 11.62M |
| ResearchAndDevelopment | 5.29M | 9.85M | 9.14M |
| SellingGeneralAndAdministration | 2.39M | 2.13M | 2.48M |
| GeneralAndAdministrativeExpense | 2.39M | 2.13M | 2.48M |
| OtherGandA | 2.39M | 2.13M | 2.48M |
| TotalRevenue | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 137.94K | 5.96K | 5.15K | 5.15K |
| ShareIssued | 137.94K | 5.96K | 5.15K | 5.15K |
| TotalDebt | 1.58M | 2.94M | 3.02M | 3.60M |
| TangibleBookValue | -5.07M | -42.06M | -34.87M | -23.43M |
| InvestedCapital | -5.07M | -41.46M | -34.87M | -23.43M |
| WorkingCapital | -3.69M | -1.54M | 5.91M | 17.69M |
| NetTangibleAssets | -1.89M | -42.06M | -34.87M | -23.43M |
| CapitalLeaseObligations | 1.58M | 2.34M | 3.02M | 3.60M |
| CommonStockEquity | -5.07M | -42.06M | -34.87M | -23.43M |
| PreferredStockEquity | 3.18M | |||
| TotalCapitalization | -1.89M | -42.06M | -34.87M | -23.43M |
| TotalEquityGrossMinorityInterest | -1.89M | -42.06M | -34.87M | -23.43M |
| StockholdersEquity | -1.89M | -42.06M | -34.87M | -23.43M |
| OtherEquityInterest | -1.30M | |||
| RetainedEarnings | -70.92M | -43.09M | -35.80M | -23.97M |
| AdditionalPaidInCapital | 67.14M | 1.03M | 928.56K | 541.87K |
| CapitalStock | 3.18M | 1.00 | 904.00 | 897.00 |
| CommonStock | 242.00 | 1.00 | 904.00 | 897.00 |
| PreferredStock | 3.18M | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 8.10M | 47.18M | 46.22M | 47.60M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 699.11K | 43.68M | 45.06M | 45.77M |
| PreferredSecuritiesOutsideStockEquity | 0.00 | 42.10M | 42.10M | 42.10M |
| DerivativeProductLiabilities | 610.38K | 647.37K | ||
| LongTermDebtAndCapitalLeaseObligation | 699.11K | 1.58M | 2.34M | 3.02M |
| LongTermCapitalLeaseObligation | 699.11K | 1.58M | 2.34M | 3.02M |
| CurrentLiabilities | 7.40M | 3.51M | 1.16M | 1.84M |
| OtherCurrentLiabilities | 20.00K | 321.99K | ||
| CurrentDebtAndCapitalLeaseObligation | 876.39K | 1.37M | 672.37K | 585.25K |
| CurrentCapitalLeaseObligation | 876.39K | 769.09K | 672.37K | 585.25K |
| CurrentDebt | 599.69K | |||
| CurrentNotesPayable | 0.00 | 599.69K | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 244.30K | 68.70K | 19.76K | 764.30K |
| PayablesAndAccruedExpenses | 6.26M | 1.75M | 471.82K | 488.69K |
| CurrentAccruedExpenses | 1.59M | 75.94K | 80.64K | 28.78K |
| InterestPayable | 0.00 | 27.64K | ||
| Payables | 4.67M | 1.67M | 391.19K | 459.92K |
| DividendsPayable | 85.50K | 0.00 | ||
| TotalTaxPayable | 78.45K | 0.00 | ||
| AccountsPayable | 4.51M | 1.67M | 391.19K | 459.92K |
| TotalAssets | 6.21M | 5.13M | 11.35M | 24.18M |
| TotalNonCurrentAssets | 2.49M | 3.16M | 4.27M | 4.65M |
| NonCurrentDeferredAssets | 500.00K | 0.00 | ||
| NetPPE | 1.99M | 3.16M | 4.27M | 4.65M |
| AccumulatedDepreciation | -2.03M | -1.59M | -1.13M | -650.89K |
| GrossPPE | 4.02M | 4.74M | 5.40M | 5.30M |
| OtherProperties | 3.97M | 4.70M | 5.35M | 5.28M |
| MachineryFurnitureEquipment | 46.75K | 46.75K | 46.75K | 26.70K |
| BuildingsAndImprovements | 2.85M | 3.44M | ||
| Properties | 0.00 | 0.00 | ||
| CurrentAssets | 3.71M | 1.97M | 7.08M | 19.52M |
| OtherCurrentAssets | 274.75K | 368.78K | 256.46K | 306.05K |
| CurrentDeferredAssets | 112.23K | 0.00 | ||
| CashCashEquivalentsAndShortTermInvestments | 3.33M | 1.60M | 6.82M | 19.22M |
| CashAndCashEquivalents | 3.33M | 1.60M | 6.82M | 19.22M |
| CashFinancial | 3.33M | 1.60M | 6.82M | 19.22M |
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| FreeCashFlow | -5.79M | -12.40M | -10.71M |
| IssuanceOfDebt | 605.23K | ||
| IssuanceOfCapitalStock | 0.00 | ||
| CapitalExpenditure | -694.23K | -612.57K | |
| EndCashPosition | 1.60M | 6.82M | 19.22M |
| BeginningCashPosition | 6.82M | 19.22M | 29.86M |
| ChangesInCash | -5.22M | -12.40M | -10.65M |
| FinancingCashFlow | 571.68K | 5.62K | 60.26K |
| CashFlowFromContinuingFinancingActivities | 571.68K | 5.62K | 60.26K |
| NetOtherFinancingCharges | -39.32K | ||
| ProceedsFromStockOptionExercised | 5.77K | 5.62K | 60.26K |
| NetPreferredStockIssuance | 0.00 | ||
| PreferredStockIssuance | 0.00 | ||
| NetIssuancePaymentsOfDebt | 605.23K | ||
| NetShortTermDebtIssuance | 0.00 | ||
| ShortTermDebtIssuance | 0.00 | ||
| NetLongTermDebtIssuance | 605.23K | ||
| LongTermDebtIssuance | 605.23K | ||
| InvestingCashFlow | -694.23K | -612.57K | |
| CashFlowFromContinuingInvestingActivities | -694.23K | -612.57K | |
| NetPPEPurchaseAndSale | -694.23K | -612.57K | |
| PurchaseOfPPE | -694.23K | -612.57K | |
| OperatingCashFlow | -5.79M | -11.71M | -10.09M |
| CashFlowFromContinuingOperatingActivities | -5.79M | -11.71M | -10.09M |
| ChangeInWorkingCapital | 540.11K | -1.30M | 492.34K |
| ChangeInOtherCurrentLiabilities | -672.37K | -585.25K | -294.65K |
| ChangeInPayablesAndAccruedExpense | 1.32M | -761.42K | 689.26K |
| ChangeInAccruedExpense | 44.24K | -692.68K | 477.09K |
| ChangeInPayable | 1.28M | -68.73K | 212.17K |
| ChangeInAccountPayable | 1.28M | -68.73K | 212.17K |
| ChangeInPrepaidAssets | -112.32K | 49.59K | 97.73K |
| OtherNonCashItems | 35.66K | ||
| StockBasedCompensation | 96.90K | 381.07K | 287.74K |
| DepreciationAmortizationDepletion | 1.12M | 1.07M | 735.47K |
| DepreciationAndAmortization | 1.12M | 1.07M | 735.47K |
| Depreciation | 1.12M | 1.07M | 735.47K |
| OperatingGainsLosses | -290.26K | -36.99K | -980.31K |
| GainLossOnInvestmentSecurities | -290.26K | -36.99K | -980.31K |
| NetIncomeFromContinuingOperations | -7.29M | -11.83M | -10.63M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CERO
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|